From Drug Discovery Informatics to Personalized Therapeutics


Day 1 | Day 2 | Download Brochure | Short Courses 

It is clear that one drug does not fit all people. The aspiration of personalized therapeutics is bringing people together through public-private collaborations from both the pharmaceutical industry and academia. In this meeting, we will showcase the latest advancement in pre-clinical models and profiling technologies that can improve our understanding of underlying mechanism of disease from various phenotypes, as well as measurements at the genomic, metabolic and proteomic level. We will also feature IT infrastructure and bioinformatics approaches to integrate genomic and medical records data and facilitate the discovery of drug mechanisms and efficacy at the individual level.

Wednesday, 10 October

12:30 Conference Registration

» Plenary Keynotes 

Big and Small Data in Regulation 

14:00 Chairperson’s Remarks

14:15 Regulatory Science and Technology: Current Strategies and New Connections

Eric PerakslisEric D. Perakslis, Ph.D., CIO and Chief Scientist of Informatics, U.S. Food and Drug Administration (FDA)


14:35 A National Regulator’s Perspective: The Challenges of Integration and Collaboration in a Decentralized Environment

Alison DavisAlison Davis, Director, Information Management, The Medicines and Healthcare Products Regulatory Agency (MHRA)


14:55 A Strategic Vision on ICT, Supporting the Evaluation and Supervision on Medicines at EMA

Luc VerhelstLuc Verhelst, CIO, European Medicines Agency (EMA)


15:15 Panel Discussion


Kevin Davies, Ph.D., Editor-in-Chief, Bio-IT World

Martin Stanley, Director, Division of Technology, U.S. Food and Drug Administration (FDA)


Alison Davis, Director, Information Management, The Medicines and Healthcare Products Regulatory Agency (MHRA)

Eric D. Perakslis, Ph.D., CIO and Chief Scientist of Informatics, U.S. Food and Drug Administration (FDA)

Luc Verhelst, CIO, European Medicines Agency (EMA)

15:45 Refreshment Break in the Exhibit Hall with Poster Viewing

Public-Private Partnership for Drug Discovery 

Parthys Reverse Informatics logo16:45 Drug Targets Synonyms Dictionary: A Heuristic Approach for Maximizing Patent Retrieval in Bio Pharmaceutical SpaceSrinivasan Parthiban, Ph.D., President & CEO of Parthys Reverse InformaticsThe variety of expressions and synonyms which refer to the actual protein object in free text is currently the main obstacle for comprehensive retrieval of target containing patents. Searches performed with our drug targets synonyms dictionary, retrieved even the obfuscated patents, generating actionable reports for you!

17:00 Enabling Partnerships and Collaboration in Life Science – Value from Pre-Competitive Activities

Veit Ulshoefer, Ph.D., Global Head, Research Informatics, Merck KGaA

Since 2009, the Pistoia Alliance has drawn significant interest from across the industry. We are focused on the highest-value, most-challenging opportunities for developing technology standards and new capabilities. The industry as a whole benefits from the efforts of Pistoia, not just any single segment. Learn the latest updates and current priorities of the Pistoia Alliance projects and how to become engaged in the Pistoia efforts. We will review the learnings from our current portfolio and how we are moving forward with key initiatives. We are keen to understand the continuing drivers in the life science industry and how pre-competitive collaboration can support this.

17:30 Accelerating Drug Development via Interoperable Digital Identities, Digital Signatures and Cloud Computing

Mollie Shields-UehlingMollie Shields-Uehling, President & CEO, SAFE Biopharma Association

The session will discuss an ongoing study involving public (National Cancer Institute) and private (Bristol-Myers Squibb, sanofi-aventis) cancer researchers demonstrating use of interoperable digital identities, digital signatures and cloud computing to accelerate initiation of a clinical trial while lowering its costs. Researchers were provisioned with interoperable US Government and SAFE-BioPharma digital identity credentials, which were used to access, amend, sign and exchange electronic documents placed in the cloud. Impressive ROI explains improvements over paper-based processes and use of courier, fax, travel, etc.

18:00 Close of Day

Day 1 | Day 2 | Download Brochure | Short Courses 

Japanese Korean Chinese Simplified Chinese Traditional 
Premier Sponsors


Hitachi Data Systems


View All Sponsors 

Premier Sponsor

Official Media Partner

Bio-IT World

View Media Partners 


Bio-IT World Events

Bio-IT World Expo Locations 
Bio-IT World Expo 

Bio-IT Cloud Summit